HCM241220C2500
- 0.00
- 0.000.00%
Hutchmed (China) Newsroom
HUTCHMED (China) Analyst Ratings
Goldman Sachs Maintains Hutchmed (China)(HCM.US) With Hold Rating, Announces Target Price $19
Hold Rating on HUTCHMED Amid Promising U.S. Launch and Pending EU Reimbursement Clarity
Goldman Sachs Keeps Their Hold Rating on HUTCHMED (HCM)
Analysts' Opinions Are Mixed on These Healthcare Stocks: HUTCHMED (HCM) and PAVmed (PAVM)
HUTCHMED Hold Rating: Cautious Optimism Amidst Stable Outlook and International Growth Potential
Maintaining Hold on HUTCHMED: Mixed FRUTIGA Results and Fair Valuation Limit Upside
Analysts Offer Insights on Healthcare Companies: Halozyme (HALO), HUTCHMED (HCM) and Plus Therapeutics (PSTV)
Deutsche Bank Upgrades HUTCHMED (China) to Buy, Raises Price Target to $22.1
HUTCHMED (China) Analyst Ratings
HUTCHMED's Global Expansion and New Product Launches Bolster Buy Rating: An Analysis of Growth Prospects and Market Potential
HUTCHMED (China) Analyst Ratings
Analysts Conflicted on These Healthcare Names: HUTCHMED (HCM), Bayer (OtherBAYRY) and Compass Therapeutics (CMPX)
Cantor Fitzgerald Reiterates Overweight on HUTCHMED (China), Maintains $50 Price Target
HUTCHMED (China) Analyst Ratings
Bank of America Securities Sticks to Its Buy Rating for HUTCHMED (HCM)
Cantor Fitzgerald Reiterates Overweight on HUTCHMED (China), Maintains $50 Price Target
HUTCHMED (China) Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Viatris (VTRS), MacroGenics (MGNX) and HUTCHMED (HCM)
Goldman Sachs Adjusts HUTCHMED (China)'s Price Target to $16 From $14, Maintains Neutral Rating